Oculis (NASDAQ:OCS) Price Target Lowered to $20.00 at JPMorgan Chase & Co.

Oculis (NASDAQ:OCS) had its price target cut by JPMorgan Chase & Co. from $23.00 to $20.00 in a research report sent to investors on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Other research analysts have also recently issued reports about the stock. Guggenheim dropped their target price on shares of Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a report on Monday, June 1st. Robert W. Baird dropped their price objective on shares of Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a research note on Monday, June 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a report on Friday, July 17th. Stifel Nicolaus reduced their price objective on shares of Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $26.00 target price on shares of Oculis in a research note on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Oculis presently has an average rating of “Moderate Buy” and an average price target of $38.00.

Oculis Trading Up 0.9%

Shares of OCS stock opened at $12.94 on Friday. The business’s fifty day moving average price is $12.19 and its 200 day moving average price is $21.84. The firm has a market capitalization of $750.26 million, a PE ratio of -7.44 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.35 and a quick ratio of 8.35. Oculis has a 1-year low of $10.52 and a 1-year high of $34.47.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share (EPS) for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. The company had revenue of $0.38 million during the quarter. As a group, sell-side analysts forecast that Oculis will post -2.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Oculis

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in shares of Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Oculis in the second quarter worth about $393,000. Bank of America Corp DE raised its position in shares of Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after purchasing an additional 878 shares in the last quarter. Woodline Partners LP raised its holdings in Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after acquiring an additional 33,265 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares in the last quarter. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.